乙型肝炎病毒感染和表观遗传治疗策略中的病毒 - 宿主 - 相

StephenW

FEBS J. 2017 Apr 29. doi: 10.1111/febs.14094. [Epub ahead of print]
Virus-host-interplay in hepatitis B virus infection and epigenetic treatment strategies.
Hensel KO1, Rendon JC2,3, Navas MC3, Rots MG2, Postberg J1.
Author information

1    HELIOS Medical Centre Wuppertal, Paediatrics Centre, Centre for Clinical & Translational Research (CCTR), Faculty of Health, Centre for Biomedical Education & Research (ZBAF), Witten/Herdecke University, Germany.
2    Epigenetic Editing, Department of Pathology and Medical Biology, University of Groningen, University Medical Center Groningen (UMCG), The Netherlands.
3    Grupo de Gastrohepatologia, Facultad de Medicina, Universidad de Antioquia, (UdeA), Medellin, Colombia.

Abstract

Worldwide, chronic hepatitis B virus (HBV) infection is a major health problem and no cure exists. Importantly, hepatocyte intrusion by HBV particles results in a complex deregulation of both viral and host cellular genetic and epigenetic processes. Among the attempts to develop novel therapeutic approaches against HBV infection, several options targeting the epigenomic regulation of HBV replication are gaining attention. These include the experimental treatment with 'epidrugs'. Moreover, as a targeted approach, the principle of 'epigenetic editing' recently is being exploited to control viral replication. Silencing of HBV by specific rewriting of epigenetic marks might diminish viral replication, viremia and infectivity, eventually controlling the disease and its complications. Additionally, epigenetic editing can be used as an experimental tool to increase our limited understanding regarding the role of epigenetic modifications in viral infections. Aiming for permanent epigenetic reprogramming of the viral genome without unspecific side-effects, this breakthrough may pave the roads for an ambitious technological pursuit: to start designing a curative approach utilizing manipulative molecular therapies for viral infections in vivo. This article is protected by copyright. All rights reserved.

This article is protected by copyright. All rights reserved.
KEYWORDS:

CRISPR/Cas; CccDNA; Epigenome; HBV; HBx; epidrugs, DNA methylation; epigenome editing; virus-host interaction

PMID:
    28457020
DOI:
    10.1111/febs.14094

StephenW

FEBS J. 2017 Apr 29. doi：10.1111 / febs.14094。 [提前印刷]
乙型肝炎病毒感染和表观遗传治疗策略中的病毒 - 宿主 - 相互作用。
Hensel KO1，Rendon JC2,3，Navas MC3，Rots MG2，Postberg J1。
作者信息

1 HELIOS医学中心伍珀塔尔，儿科中心，临床和转化研究中心（CCTR），卫生学院，生物医学教育与研究中心（ZBAF），德国维滕/赫德克大学。
2表观遗传编辑，格罗宁根大学病理与医学生物学系，荷兰格罗宁根大学医学中心（联电）。
3 Grupo de Gastrohepatologia，Facultad de Medicina，Antioquia Universidad de Antioquia（UdeA），Medellin，Colombia。

抽象

世界范围内，慢性乙型肝炎病毒（HBV）感染是一个主要的健康问题，无法治愈。重要的是，肝细胞侵入HBV颗粒导致病毒和宿主细胞遗传和表观遗传过程复杂的失调。在开发针对HBV感染的新型治疗方法的尝试中，针对HBV复制的表观基因调控的几个选择正在受到重视。这些包括用“药物”进行的实验性治疗。此外，作为目标方法，最近正在利用“表观遗传编辑”的原理来控制病毒复制。通过特异性重写表观遗传标记来沉默HBV可能会减少病毒复制，病毒血症和感染性，最终控制疾病及其并发症。此外，表观遗传编辑可以用作实验工具，以增加我们对表观遗传修饰在病毒感染中的作用的有限理解。针对病毒基因组的永久表观遗传重编程而无特异性副作用，这一突破可能铺平道路进行雄心勃勃的技术追求：开始设计一种利用操纵分子治疗病毒感染的治疗方法。本文受版权保护。版权所有。

本文受版权保护。版权所有。
关键词：

CRISPR / Cas; CccDNA;表观基因组HBV; HBx;药物，DNA甲基化;表观基因组编辑;病毒主机交互

PMID：
    28457020
DOI：

oldbaby331

英文原文链接  https://share.weiyun.com/159cd2366a8e7f8e2183703e5a6fcef5
我已经下载下来。